BioMérieux recently entered a strategic investment partnership with Accunome Biotechnology Co., Limited ("Accunome"), which includes an equity investment and an exclusive distribution agreement. This partnership signifies a deep collaboration between BioMérieux and Accunome, marking an accelerated growth trajectory for BioMérieux's molecular diagnostics segment in China.

CEC Capital acted as the exclusive financial advisor to BioMérieux China in this transaction.

BioMérieux has been dedicated to providing advanced diagnostic solutions for Chinese patients, particularly in the field of infectious diseases diagnosis. In recent years, infectious diseases have gained significant attention from both medical professionals and patients. Advanced biotechnology diagnostic products have the potential to greatly enhance the speed and accuracy of diagnostics, enabling early identification, control, and treatment of infectious diseases, thereby safeguarding public health.

Established in 2018, Accunome is a technology-driven high-tech enterprise with research and development, GMP production, sales, and service centers in Zhejiang Jiaxing, Shanghai, and San Diego, USA. The company is committed to providing fully automated molecular diagnostic solutions for infectious and critical illnesses. Its first-generation molecular diagnostic platform, DXcellence12, integrates nucleic acid extraction, amplification, and detection into one. As a fully automated universal molecular diagnostic device, DXcellence12 allows direct sample-to-machine processing, with all operational steps, including sample loading, completed automatically by the instrument. The product has obtained the Class III registration certificate from the National Medical Products Administration and the CE certification from the European Union in 2022.